Fiera Capital Corp Increases Stock Holdings in Neurocrine Biosciences, Inc. $NBIX

Fiera Capital Corp boosted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 32.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 637,408 shares of the company’s stock after purchasing an additional 157,732 shares during the period. Fiera Capital Corp owned about 0.64% of Neurocrine Biosciences worth $90,404,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Los Angeles Capital Management LLC lifted its position in shares of Neurocrine Biosciences by 7.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company’s stock valued at $178,248,000 after buying an additional 88,522 shares in the last quarter. Cookson Peirce & Co. Inc. purchased a new position in shares of Neurocrine Biosciences during the 4th quarter valued at about $15,214,000. Havemeyer Place LP purchased a new position in shares of Neurocrine Biosciences during the 4th quarter valued at about $283,000. Vestcor Inc lifted its position in shares of Neurocrine Biosciences by 7.4% during the 4th quarter. Vestcor Inc now owns 24,424 shares of the company’s stock valued at $3,464,000 after buying an additional 1,680 shares in the last quarter. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in shares of Neurocrine Biosciences during the 4th quarter valued at about $499,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on NBIX shares. Morgan Stanley lifted their price objective on Neurocrine Biosciences from $185.00 to $191.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Wall Street Zen raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 25th. HC Wainwright lifted their price objective on Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Royal Bank Of Canada lifted their price objective on Neurocrine Biosciences from $180.00 to $183.00 and gave the company an “outperform” rating in a research report on Friday, May 29th. Finally, The Goldman Sachs Group started coverage on Neurocrine Biosciences in a research report on Tuesday, June 2nd. They set a “buy” rating and a $213.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $187.52.

Insider Activity at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 2,261 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $156.71, for a total transaction of $354,321.31. Following the sale, the insider owned 16,225 shares of the company’s stock, valued at approximately $2,542,619.75. This trade represents a 12.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Charles Gorman sold 245,088 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $154.33, for a total value of $37,824,431.04. Following the sale, the director directly owned 511,293 shares in the company, valued at $78,907,848.69. This trade represents a 32.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 328,984 shares of company stock worth $50,986,985 in the last three months. Corporate insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $163.88 on Monday. The business’s 50 day moving average is $142.73 and its 200 day moving average is $139.68. The company has a market capitalization of $16.48 billion, a PE ratio of 25.25, a price-to-earnings-growth ratio of 1.23 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 12-month low of $122.14 and a 12-month high of $169.57.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.